CYP19A1 and breast carcinoma: Patients with estrogen receptor α (ERα)-positive breast cancer are candidates for treatment with endocrine therapies such as the selective estrogen receptor modulator (SERM) tamoxifen (TAM), aromatase inhibitors (AIs) letrozole, anastrozole, or exemestane or the selective estrogen receptor downregulator (SERD), fulvestrant.